[Graves' ophthalmopathy].
Graves' orbitopathy is part of an autoimmune systemic disease which compiles hyperthyroidism, orbitopathy, dermopathy and acropachy. Stimulating antibodies against the TSH receptor play the central pathogenetic role. Main symptoms of Graves' orbitopathy comprise soft tissue inflammation, proptosis impairment of ocular motility and lid retraction. Inflammatory reactions of orbital fibroblasts are responsible for the symptoms. To restrict damage anti-inflammatory therapy (mainly systemic steroids, orbital irradiation) is indicated in moderate to severe active disease stages, and surgical orbital decompression in sight threatening states. In mild cases expectant strategy and selenium administration is sufficient. In inactive disease stages surgery is performed to improve appearance and function. Restoring euthyroidism leads to improvement of Graves' orbitopathy in about 60% of the patients. Radioiodine therapy without glucocorticoids is associated with a small but significant risk (15%) of deterioration or relapse. Thyroidectomy is neutral in later stages but may improve Graves' orbitopathy in early active stages.
Eckstein
A
A
Zentrum für Augenheilkunde, Universitätsklinikum, Hufelandstrasse 55 , 45122, Essen, Deutschland. anja.eckstein@uk-essen.de
Esser
J
J
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D049970:Graves Ophthalmopathy / Q000097:blood / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D013965:Thyroidectomy
D000893:Anti-Inflammatory Agents; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals
J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40
15998777
Am J Ophthalmol. 1993 Nov 15;116(5):533-47
8238212
Lancet. 2000 Apr 29;355(9214):1505-9
10801172
Br J Ophthalmol. 2003 Jun;87(6):773-6
12770979
J Endocrinol Invest. 2004 Mar;27(3):254-8
15165001
J Clin Endocrinol Metab. 1995 Sep;80(9):2830-3
7673432
Thyroid. 2002 Oct;12(10):855-60
12487767
Eur J Endocrinol. 2001 May;144(5):475-83
11331213
Ann Intern Med. 1998 Oct 15;129(8):632-5
9786811
Br J Ophthalmol. 2009 Aug;93(8):1052-6
19221109
Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):406-11
17039420
Eur J Endocrinol. 2007 Jan;156(1):33-40
17218723
Thyroid. 2000 Dec;10(12):1093-100
11201855
Eye (Lond). 2005 Dec;19(12):1286-9
15550932
N Engl J Med. 1998 Jan 8;338(2):73-8
9420337
Eur J Clin Invest. 1986 Oct;16(5):415-22
3100309
Clin Endocrinol (Oxf). 1996 Oct;45(4):477-81
8959089
Clin Endocrinol (Oxf). 1999 Oct;51(4):503-8
10583319
J Clin Endocrinol Metab. 2007 Jan;92(1):59-64
17047020
Curr Opin Endocrinol Diabetes Obes. 2008 Oct;15(5):446-52
18769218
Z Arztl Fortbild Qualitatssich. 2004 May;98 Suppl 5:45-53
15255313
Ophthalmology. 2008 Feb;115(2):398-409
18082885
J Endocrinol Invest. 2004 Mar;27(3):265-71
15165003
Clin Immunol. 2009 Mar;130(3):252-8
18964302
J Clin Endocrinol Metab. 2006 Sep;91(9):3464-70
16835285
J Clin Endocrinol Metab. 2004 Jan;89(1):15-20
14715820
J Clin Endocrinol Metab. 2005 Sep;90(9):5321-3
15985483
Clin Endocrinol (Oxf). 1995 Jan;42(1):45-50
7889631
Eur J Endocrinol. 2008 Mar;158(3):273-85
18299459
J Clin Endocrinol Metab. 2001 Aug;86(8):3562-7
11502779
Am J Ophthalmol. 1996 Apr;121(4):426-34
8604736
N Engl J Med. 1992 Jun 25;326(26):1733-8
1489388
Clin Endocrinol (Oxf). 2007 Oct;67(4):607-12
17880407
Eur J Endocrinol. 2006 Sep;155(3):387-9
16914591
Ophthalmologe. 2007 Sep;104(9):771-6
17823804
Eur J Endocrinol. 2008 Nov;159(5):609-15
18628345
Med Klin (Munich). 2009 May 15;104(5):343-8
19444414